Correvio Pharma Corp. is a specialty pharmaceutical company focused on providing innovative, high-quality brands that meet the needs of acute care physicians and patients. With a commercial presence and distribution network covering over 60 countries worldwide, Correvio develops, acquires and commercializes brands for the in-hospital, acute care market segment. The Company's portfolio of approved and marketed brands includes: Xydalba™ (dalbavancin hydrochloride), for the treatment of acute bacterial skin and skin structure infections (ABSSSI); Zevtera®/Mabelio® (ceftobiprole medocaril sodium), a cephalosporin antibiotic for the treatment of community- and hospital-acquired pneumonia (CAP, HAP); Brinavess® (vernakalant IV) for the rapid conversion of recent onset atrial fibrillation to sinus rhythm; Aggrastat® (tirofiban hydrochloride) for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome. Correvio's pipeline of product candidates includes Trevyent®, a drug device combination that is designed to deliver treprostinil, the world's leading treatment for pulmonary arterial hypertension.
Company profile
Ticker
CORV
Exchange
Website
CEO
Mark H. N. Corrigan
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Cardiome Pharma Corp, Cardiome Pharma Corp, Nortran Pharmaceuticals Inc
SEC CIK
Corporate docs
CORV stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
9 Jun 20
EFFECT
Notice of effectiveness
28 May 20
EFFECT
Notice of effectiveness
28 May 20
6-K
Current report (foreign)
27 May 20
25-NSE
Exchange delisting
27 May 20
F-10POS
Automatic registration of securities (post-effective amendment, Canada)
27 May 20
POS AM
Prospectus update (post-effective amendment)
27 May 20
POS AM
Prospectus update (post-effective amendment)
27 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
27 May 20
S-8 POS
Registration of securities for employees (post-effective amendment)
27 May 20
Latest ownership filings
SC 13G/A
Klein Roger M.
26 May 20
SC 13G
Klein Roger M.
16 Apr 20
SC 13G
Correvio Pharma Corp.
24 Feb 20
SC 13G/A
Correvio Pharma Corp.
14 Feb 20
SC 13G/A
Correvio Pharma Corp.
13 Feb 20
SC 13G/A
Correvio Pharma Corp.
7 Jan 20
SC 13G/A
Correvio Pharma Corp.
4 Sep 19
SC 13G/A
Correvio Pharma Corp.
5 Apr 19
SC 13G
Correvio Pharma Corp.
15 Feb 19
SC 13G/A
Correvio Pharma Corp.
15 Feb 19
Institutional ownership, Q3 2021
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|